Multi-Gram Scale Synthesis and Characterization of Mometasone Furoate EP Impurity C.

mometasone furoate mometasone furoate EP impurity C steroid synthesis of APIs impurities

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
30 Nov 2023
Historique:
received: 07 11 2023
revised: 23 11 2023
accepted: 28 11 2023
medline: 9 12 2023
pubmed: 9 12 2023
entrez: 9 12 2023
Statut: epublish

Résumé

Mometasone furoate is a synthetic corticosteroid used in the treatment of skin inflammatory conditions, hay fever and asthma. The industrial manufacturing routes to mometasone furoate are generally accompanied by the formation of numerous process impurities that need to be detected and quantified, as requested by regulatory authorities. The ready availability of such impurities in the required quantity and purity is therefore essential for toxicological studies, analytical method development and process validation. Herein, we report the multi-gram scale preparation of 21'-chloro-(16'α-methyl-3',11',20'-trioxo-pregna-1',4'-dien-17'-yl)-furan-2-carboxylate (mometasone furoate EP impurity C), one of the known impurities of mometasone furoate. This study also includes the systematic investigation of the final acylation step, as well as the characterization of the difuroate enol ether intermediate and its conversion to the target impurity C.

Identifiants

pubmed: 38067588
pii: molecules28237859
doi: 10.3390/molecules28237859
pmc: PMC10708511
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Newchem SpA, Verona, Italy
ID : n.a.

Références

Steroids. 1995 Sep;60(9):612-4
pubmed: 8545849
Steroids. 2019 Aug;148:47-55
pubmed: 31075340
J Med Chem. 1987 Sep;30(9):1581-8
pubmed: 3625707
Drugs. 1998 Jan;55(1):145-63
pubmed: 9463794
Multidiscip Respir Med. 2016 May 02;11:18
pubmed: 27141307
J Am Chem Soc. 1966 Jul 5;88(13):3016-21
pubmed: 5941536
Ther Clin Risk Manag. 2008 Dec;4(6):1201-8
pubmed: 19337427

Auteurs

Riccardo Ronchetti (R)

Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06122 Perugia, Italy.

Luigi Alfonso Pannone (LA)

Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06122 Perugia, Italy.

Bruno Cerra (B)

Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06122 Perugia, Italy.

Emidio Camaioni (E)

Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06122 Perugia, Italy.

Gianfranco Lopopolo (G)

Research & Development Department, Newchem SpA, Via Roveggia, 47, 37136 Verona, Italy.

Emanuele Attolino (E)

Research & Development Department, Newchem SpA, Via Roveggia, 47, 37136 Verona, Italy.

Antimo Gioiello (A)

Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06122 Perugia, Italy.

Classifications MeSH